Potential of Infrared Imaging for Breast Cancer Detection: A Critical Evaluation

2021 ◽  
Author(s):  
Alyssa Owens ◽  
Satish G. Kandlikar ◽  
Pradyumna Phatak
Keyword(s):  
Breast Cancer ◽  
Infrared Imaging ◽  
Breast Cancer Mortality ◽  
Critical Evaluation ◽  
Infrared Image ◽  
Screening Mammography ◽  
Patient Specific ◽  
Major Drawback ◽  
Modeling And Analysis ◽  
Dense Breast Tissue

Abstract Screening for breast cancer to detect the disease in an early curable stage remains our most important tool to reduce breast cancer mortality and routine screening mammography is recommended. Although the technique has been refined, screening mammography has significant shortfalls. A major drawback is the occurrence of "dense breast tissue" which obscures mammography images leading to missed cancer diagnoses. Adjunctive imaging technology has been used in this setting. This review provides a critical evaluation of infrared image (IRI) protocols and assessment techniques employed by previous researchers since the inception of this technology in 1956. The prevalence of empirical approach is identified as a major area of concern and recent scientific approaches utilizing mathematical modeling and analysis with patient-specific geometries are strongly advised. Such efforts and subsequent validation are essential before the IRI can be widely used in the mainstream breast cancer screening as an adjunctive tool.

scholarly journals Screening for breast cancer in 2018— what should we be doing today?

2018 ◽  
Vol 25 ◽  
pp. 115 ◽  
Author(s):  
J.M. Seely ◽  
T. Alhassan
Keyword(s):  
Breast Cancer ◽  
Breast Biopsy ◽  
Breast Cancer Mortality ◽  
Digital Breast Tomosynthesis ◽  
Screening Mammography ◽  
False Positives ◽  
Breast Cancers ◽  
False Negatives ◽  
Dense Breast Tissue ◽  
Additional Imaging

Although screening mammography has delivered many benefits since its introduction in Canada in 1988, questions about perceived harms warrant an up-to-date review. To help oncologists and physicians provide optimal patient recommendations, the literature was reviewed to find the latest guidelines for screening mammography, including benefits and perceived harms of overdiagnosis, false positives, false negatives, and technologic advances.For women 40–74 years of age who actually participate in screening every 1–2 years, breast cancer mortality is reduced by 40%. With appropriate corrections, overdiagnosis accounts for 10% or fewer breast cancers. False positives occur in about 10% of screened women, 80% of which are resolved with additional imaging, and 10%, with breast biopsy. An important limitation of screening is the false negatives (15%–20%). The technologic advances of digital breast tomosynthesis, breast ultrasonography, and magnetic resonance imaging counter the false negatives of screening mammography, particularly in women with dense breast tissue.

Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years

2020 ◽  
Vol 172 (6) ◽  
pp. 381 ◽  
Author(s):  
Xabier García-Albéniz ◽  
Miguel A. Hernán ◽  
Roger W. Logan ◽  
Mary Price ◽  
Katrina Armstrong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Screening Mammography ◽  
Annual Screening

scholarly journals Service screening mammography reduces breast cancer mortality among elderly women in Turku

2006 ◽  
Vol 13 (1) ◽  
pp. 34-40 ◽  
Author(s):  
I Parvinen ◽  
H Helenius ◽  
L Pylkkänen ◽  
A Anttila ◽  
P Immonen-Räihä ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Elderly Women ◽  
Breast Cancer Mortality ◽  
Screening Mammography

scholarly journals Impact of screening mammography on breast cancer mortality

2015 ◽  
Vol 138 (8) ◽  
pp. 2003-2012 ◽  
Author(s):  
Archie Bleyer ◽  
Cornelia Baines ◽  
Anthony B. Miller
Keyword(s):  
Breast Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Screening Mammography

Original Paper: Contribution of clinical breast examination to mammography screening in the early detection of breast cancer

2003 ◽  
Vol 10 (1) ◽  
pp. 16-21 ◽  
Author(s):  
C Bancej ◽  
K Decker ◽  
A Chiarelli ◽  
M Harrison ◽  
D Turner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Breast Cancer Mortality ◽  
Clinical Breast Examination ◽  
Screening Mammography ◽  
Detection Rates ◽  
Breast Examination ◽  
Mode Of Detection ◽  
Clinical Breast ◽  
Interim Measures

Objectives: As the benefit of clinical breast examination (CBE) over that of screening mammography alone in reducing breast cancer mortality is uncertain, it is informative to monitor its contribution to interim measures of effectiveness of a screening programme. Here, the contribution of CBE to screening mammography in the early detection of breast cancer was evaluated. Setting: Four Canadian organised breast cancer screening programmes. Methods: Women aged 50-69 receiving dual screening (CBE and mammography) (n=300,303) between 1996 and 1998 were followed up between screen and diagnosis. Outcomes assessed by mode of detection (CBE alone, mammography alone, or both CBE and mammography) included referral rate, positive predictive value, pathological features of tumours (size, nodal status, morphology), and cancer detection rates overall and for small cancers (≤10 mm or node-negative). Heterogeneity in findings across programmes was also assessed. Results: On first versus subsequent screen, CBE alone resulted in 28.5-36.7% of referrals, and 4.6-5.9% of cancers compared with 52.6-60.1% of referrals and 60.0-64.3% of cancers for mammography alone. Among cancers detected by CBE, 83.6-88.6% were also detected by mammography, whereas for mammographically detected cancers only 31.7-37.2% were also detected by CBE. On average, CBE increased the rate of detection of small invasive cancers by 2-6% over rates if mammography was the sole detection method. Without CBE, programmes would be missing three cancers for every 10,000 screens and 3-10 small invasive cancers in every 100,000 screens. Conclusions: Inclusion of CBE in an organised programme contributes minimally to early detection.

The effect of mammography screening regimen on incidence-based breast cancer mortality

2018 ◽  
Vol 25 (4) ◽  
pp. 197-204 ◽  
Author(s):  
Martin J Yaffe ◽  
Nicole Mittmann ◽  
Oguzhan Alagoz ◽  
Amy Trentham-Dietz ◽  
Anna NA Tosteson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Temporal Distribution ◽  
Screening Mammography ◽  
Breast Cancers ◽  
Breast Cancer Death ◽  
Life Years ◽  
Life Years Lost ◽  
The Mean

Objectives Incidence-based mortality quantifies the distribution of cancer deaths and life-years lost, according to age at detection. We investigated the temporal distribution of the disease burden, and the effect of starting and stopping ages and interval between screening mammography examinations, on incidence-based mortality. Methods Incidence-based mortality was estimated using an established breast cancer simulation model, adapted and validated to simulate breast cancer incidence, screening performance, and delivery of therapies in Canada. Ten strategies were examined, with varying starting age (40 or 50), stopping age (69 or 74), and interval (1, 2, 3 years), and “No Screening.” Life-years lost were computed as the difference between model predicted time of breast cancer death and that estimated from life tables. Results Without screening, 70% of the burden in terms of breast cancer deaths extends between ages 45 and 75. The mean of the distribution of ages of detection of breast cancers that will be fatal in an unscreened population is 61.8 years, while the mean age of detection weighted by the number of life-years lost is 55, a downward shift of 6.8 years. Similarly, the mean age of detection for the distribution of life-years gained through screening is lower than that for breast cancer deaths averted. Conclusion Incidence-based mortality predictions from modeling elucidate the age dependence of the breast cancer burden and can provide guidance for optimizing the timing of screening regimens to achieve maximal impact. Of the regimens studied, the greatest lifesaving effect was achieved with annual screening beginning at age 40.

scholarly journals Breast cancer mortality and screening mammography in New Zealand: Incidence-based and aggregate analyses

2018 ◽  
Vol 26 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Richard Taylor ◽  
Marli Gregory ◽  
Kerry Sexton ◽  
Jessica Wharton ◽  
Nisha Sharma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
New Zealand ◽  
Cancer Mortality ◽  
Mammography Screening ◽  
Breast Cancer Mortality ◽  
Primary Treatment ◽  
Screening Mammography ◽  
Randomized Controlled ◽  
Before And After ◽  
Incident Cases

Objective To investigate trends in breast cancer mortality in New Zealand women, to corroborate or negate a causal association with service screening mammography. Method Cumulated mortality rates from breast cancer deaths individually linked to incident cases diagnosed before and after screening commencement were compared, in women aged 50–64 (from 2001) and aged 45–49 and 65–69 (from 2006). Trends and differences in aggregate invasive breast cancer mortality (1975–2013) were assessed in relation to introduction of mammography screening targeting women aged 50–64 and 45–69. Joinpoint analysis was also undertaken. Results The reduction in incidence-based cumulated breast cancer mortality before and after the introduction of screening was −15% (p = 0.006) for women aged 45–69, and 17% (p = 0.005) for those aged 50–64. Aggregate mortality declined by −34% (2005–13 compared with 1992–98) in the age group 50–64, and by –28% among women aged 45–49 and –25% among women aged 65–74. For women aged 50–64 the 2-joinpoint model shows a 1990 turning point, from prior rising mortality to a mean −1.8% decline per annum, coinciding with improvements in primary treatment of breast cancer; and a steepening of the decline (−3.0% p.a.) from the late 1990s, coinciding with the introduction of service mammography screening. Conclusion Breast cancer mortality declines occurring since the advent of screening mammography in New Zealand are consistent with other incidence-based and aggregate studies of screening mammography in populations, individual-based cohort studies, and randomized controlled trials.

Sign in / Sign up

Export Citation Format

Share Document